Clostridium difficile infection (CDI) is known to be associated with prior exposure to many
classes of antibiotics. Standard therapy for CDI (ie, metronidazole and vancomycin) is …

Objectives: Data on the risk of Clostridium difficile infection (CDI) associated with specific
antibiotics are difficult to obtain because of confounding clinical factors. It is particularly …

Background Clostridium difficile infection (CDI) is mediated by potent extracellular toxins
and is spread largely via bacterial spores. We and others have shown that some antibiotics …

Broad-spectrum antibiotics are often associated with a relatively high risk of Clostridium
difficile infection (CDI). However, exceptions to this rule, eg, piperacillin–tazobactam, show …

The glycylcycline antibiotic tigecycline was approved in 2005 for the treatment of
complicated skin and soft tissue infections and complicated intra-abdominal infections …

Introduction Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhea.
Metronidazole and vancomycin are the primary treatment options for CDI, but increasing …

Objective: To evaluate the evidence for the use of tigecycline in the treatment of Clostridium
difficile infection (CDI). Data Sources: Searches were performed (2004 to June 2011), using …

The current study was designed to evaluate the in vitro activity of tigecycline and comparator
antimicrobials against Clostridium difficile isolates collected from hospitals in Europe during …

Tigecycline is a broad-spectrum glycylcycline antibiotic with potent in vitro activity against
Clostridium difficile. We used a mouse model to test the hypothesis that tigecycline has a low …

Clostridium difficile infection (CDI) has become more refractory to standard therapy. We
describe 4 patients with severe refractory CDI who were successfully treated with …